Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
J. Scott Wolchko, insider at Fate Therapeutics
J. Scott Wolchko Insider Alerts

Get notified the next time J. Scott Wolchko buys or sells Fate Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

J. Scott Wolchko Insider Information

Mr. Wolchko is the President & Chief Executive Officer at Fate Therapeutics and is responsible for the company’s finance, administration and operations. Mr. Wolchko began his career as an investment banker with Morgan Stanley & Co., where he served for six years in the firm’s New York City and Menlo Park, California offices. As a member of Morgan Stanley’s Investment Banking Health Care Group, he assisted emerging growth companies in the health care technology sector complete capital-raising and M&A transactions. Prior to joining Fate Therapeutics, Mr. Wolchko served as the Chief Financial Officer of Bocada, Inc., where he oversaw all corporate service-related operations, and previously led Corporate Development at drugstore.com, where he was responsible for sourcing, evaluating and executing financial and business development opportunities. Mr. Wolchko holds an M.S. in biochemical engineering from the University of Virginia, and a B.S. in biomedical engineering from the University of Vermont.

What is J. Scott Wolchko's net worth?

The estimated net worth of J. Scott Wolchko is at least $20.34 million as of April 23rd, 2021. Mr. Wolchko owns 423,793 shares of Fate Therapeutics stock worth more than $20,342,064 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Wolchko may own. Learn More.

How do I contact J. Scott Wolchko?

The corporate mailing address for Mr. Wolchko and other Fate Therapeutics executives is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics can also be reached via phone at (858) 875-1800 and via email at [email protected]

Has J. Scott Wolchko been buying or selling shares of Fate Therapeutics?

During the last quarter, J. Scott Wolchko has sold $2,892,000.00 of Fate Therapeutics stock. Most recently, J Scott Wolchko sold 20,000 shares of the business's stock in a transaction on Thursday, November 18th. The shares were sold at an average price of $54.27, for a transaction totalling $1,085,400.00.

Who are Fate Therapeutics' active insiders?

Fate Therapeutics' insider roster includes Yu-Waye Chu (VP), Edward Dulac, III (CFO), Louis Petrillo (Insider), Cindy Tahl (General Counsel), Bahram Valamehr (Insider), and J. Wolchko (CEO).

Are insiders buying or selling shares of Fate Therapeutics?

In the last year, Fate Therapeutics insiders bought shares 1 times. They purchased a total of 327,485 shares worth more than $27,999,967.50. In the last year, insiders at the biopharmaceutical company sold shares 22 times. They sold a total of 563,220 shares worth more than $50,291,801.27. The most recent insider tranaction occured on November, 18th when CEO J Scott Wolchko sold 20,000 shares worth more than $1,085,400.00. Insiders at Fate Therapeutics own 18.6 % of the company.

Information on this page was last updated on 11/18/2021.

J. Scott Wolchko Insider Trading History at Fate Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/18/2021Sell20,000$54.27$1,085,400.00View SEC Filing Icon  
10/21/2021Sell30,000$60.22$1,806,600.00View SEC Filing Icon  
8/19/2021Sell20,000$88.01$1,760,200.00View SEC Filing Icon  
7/22/2021Sell30,000$86.05$2,581,500.00View SEC Filing Icon  
4/23/2021Sell30,000$85.24$2,557,200.00423,793View SEC Filing Icon  
1/21/2021Sell30,000$103.05$3,091,500.00393,793View SEC Filing Icon  
1/11/2021Sell69,407$116.33$8,074,116.31393,065View SEC Filing Icon  
1/8/2021Sell60,820$117.10$7,122,022.00393,065View SEC Filing Icon  
11/13/2020Sell60,000$51.87$3,112,200.00
1/30/2020Sell25,000$25.45$636,250.00444,969View SEC Filing Icon  
12/20/2019Sell25,000$20.17$504,250.00378,969View SEC Filing Icon  
10/15/2019Sell21,017$14.44$303,485.48View SEC Filing Icon  
5/16/2019Sell14,335$19.37$277,668.95389,216View SEC Filing Icon  
4/17/2019Sell8,541$16.17$138,107.97375,973View SEC Filing Icon  
3/21/2019Sell20,000$17.61$352,200.00View SEC Filing Icon  
4/1/2014Sell20,000$9.64$192,800.00View SEC Filing Icon  
See Full Table

J. Scott Wolchko Buying and Selling Activity at Fate Therapeutics

This chart shows J Scott Wolchko's buying and selling at Fate Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fate Therapeutics Company Overview

Fate Therapeutics logo
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $48.00
Low: $47.01
High: $53.02

50 Day Range

MA: $57.15
Low: $48.00
High: $64.85

2 Week Range

Now: $48.00
Low: $47.01
High: $121.16

Volume

1,231,769 shs

Average Volume

804,335 shs

Market Capitalization

$4.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!